Thérapies de Conversion

Prognostic outcomes of surgery vs. non-surgery in initially unresectable HCC with successful conversion via ICI + TKI therapy.

Sun Z, Wang Y, Tan Z, Zhou J, Chen X, Li O, Peng C

BMC Gastroenterol . 2026;26 (1)

📅 13/02/2026 PMID : 41688924 DOI : 10.1186/s12876-026-04677-w

Résumé

BACKGROUND: No consensus exists on optimal post-conversion therapy for initially unresectable hepatocellular carcinoma (uHCC) patients responding to a combination of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs). This study evaluated surgical benefits and prognostic factors in such patients. METHODS: Retrospective analysis of 67 uHCC patients receiving ICIs + TKIs conversion therapy. Log-rank test compared OS/PFS between surgical resection (SR, n = 30) and non-surgical (NSR, n = 37) groups; Cox regression identified prognostic factors. RESULTS: Baseline variables were balanced between groups. The SR group showed significantly higher PFS than the NSR group (P = 0.032), with 1-, 2-, and 3-year rates of 82.6%, 53.5%, and 31.2% versus 71.1%, 21.6%, and 14.4% for the NSR group. Partial response (PR) (HR = 6.0, P